315 related articles for article (PubMed ID: 19249390)
1. Elevated serum levels of M30 and M65 in patients with locally advanced head and neck tumors.
Ozturk B; Coskun U; Sancak B; Yaman E; Buyukberber S; Benekli M
Int Immunopharmacol; 2009 May; 9(5):645-8. PubMed ID: 19249390
[TBL] [Abstract][Full Text] [Related]
2. Is there any impact of plasma M30 and M65 levels on progression-free survival of patients with advanced gastric cancer?
Bilici A; Ustaalioglu BB; Ercan S; Orcun A; Seker M; Salepci T; Gumus M
Cancer Chemother Pharmacol; 2011 Aug; 68(2):309-16. PubMed ID: 20967544
[TBL] [Abstract][Full Text] [Related]
3. Caspase-cleaved cytokeratin 18 fragment (M30) as marker of postoperative residual tumor load in colon cancer patients.
Ausch C; Buxhofer-Ausch V; Olszewski U; Hinterberger W; Ogris E; Schiessel R; Hamilton G
Eur J Surg Oncol; 2009 Nov; 35(11):1164-8. PubMed ID: 19254831
[TBL] [Abstract][Full Text] [Related]
4. The levels of caspase-cleaved cytokeratin 18 are elevated in serum from patients with lung cancer and helpful to predict the survival.
Ulukaya E; Yilmaztepe A; Akgoz S; Linder S; Karadag M
Lung Cancer; 2007 Jun; 56(3):399-404. PubMed ID: 17316892
[TBL] [Abstract][Full Text] [Related]
5. Serum M65 as a biomarker for metastatic renal cell carcinoma.
Yildiz I; Sen F; Kilic L; Keskin S; Duranyildiz D; Bilgin E; Disci R; Ekenel M; Darendeliler E; Bavbek S; Basaran M
Clin Genitourin Cancer; 2013 Sep; 11(3):290-6. PubMed ID: 23391372
[TBL] [Abstract][Full Text] [Related]
6. Serum levels of interleukin-6 in patients with primary head and neck squamous cell carcinoma.
Riedel F; Zaiss I; Herzog D; Götte K; Naim R; Hörmann K
Anticancer Res; 2005; 25(4):2761-5. PubMed ID: 16080523
[TBL] [Abstract][Full Text] [Related]
7. Serum nitric oxide levels in patients with head and neck squamous cell carcinoma.
Kizilay A; Kalcioğlu MT; Ozuğurlu F; Ozyurt H; Aladağ I; Ozturan O; Akyol O
Kulak Burun Bogaz Ihtis Derg; 2007; 17(3):148-51. PubMed ID: 17873505
[TBL] [Abstract][Full Text] [Related]
8. Utilization of cytokeratin-based biomarkers for pharmacodynamic studies.
Linder S; Olofsson MH; Herrmann R; Ulukaya E
Expert Rev Mol Diagn; 2010 Apr; 10(3):353-9. PubMed ID: 20370591
[TBL] [Abstract][Full Text] [Related]
9. Clinical significance of serum M30 and M65 levels in melanoma.
Tas F; Karabulut S; Serilmez M; Yildiz I; Sen F; Ciftci R; Duranyildiz D
Melanoma Res; 2013 Oct; 23(5):390-5. PubMed ID: 23812330
[TBL] [Abstract][Full Text] [Related]
10. Clinical significance of serum M30 and M65 levels in patients with breast cancer.
Tas F; Karabulut S; Yildiz I; Duranyildiz D
Biomed Pharmacother; 2014 Oct; 68(8):1135-40. PubMed ID: 25465151
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of soluble adhesion molecules CD44 (CD44st, CD44v5, CD44v6), ICAM-1, and VCAM-1 as tumor markers in head and neck cancer.
Kawano T; Yanoma S; Nakamura Y; Shiono O; Kokatu T; Kubota A; Furukawa M; Tsukuda M
Am J Otolaryngol; 2005; 26(5):308-13. PubMed ID: 16137528
[TBL] [Abstract][Full Text] [Related]
12. The prognostic significance of the increase in the serum M30 and M65 values after chemotherapy and relationship between these values and clinicopathological factors in patients with advanced gastric cancer.
Bilici A; Ustaalioglu BB; Ercan S; Seker M; Yilmaz BE; Orcun A; Gumus M
Tumour Biol; 2012 Dec; 33(6):2201-8. PubMed ID: 22890829
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic and prognostic significance of cell death and macrophage activation markers in patients with hepatocellular carcinoma.
Waidmann O; Köberle V; Bettinger D; Trojan J; Zeuzem S; Schultheiß M; Kronenberger B; Piiper A
J Hepatol; 2013 Oct; 59(4):769-79. PubMed ID: 23792028
[TBL] [Abstract][Full Text] [Related]
14. Plasma glutathione S-transferase P1-1 levels in patients with head and neck squamous cell carcinoma.
Oude Ophuis MB; Mulder TP; Peters WH; Manni JJ
Cancer; 1998 Jun; 82(12):2434-8. PubMed ID: 9635537
[TBL] [Abstract][Full Text] [Related]
15. The significance of Tenascin-C serum level as tumor marker in squamous cell carcinoma of the head and neck.
Pauli C; Stieber P; Schmitt UM; Andratschke M; Hoffmann K; Wollenberg B
Anticancer Res; 2002; 22(5):3093-7. PubMed ID: 12530049
[TBL] [Abstract][Full Text] [Related]
16. Specific demonstration of drug-induced tumour cell apoptosis in human xenografts models using a plasma biomarker.
Olofsson MH; Cummings J; Fayad W; Brnjic S; Herrmann R; Berndtsson M; Hodgkinson C; Dean E; Odedra R; Wilkinson RW; Mundt KE; Busk M; Dive C; Linder S
Cancer Biomark; 2009; 5(3):117-25. PubMed ID: 19407366
[TBL] [Abstract][Full Text] [Related]
17. Serum M30 levels are associated with survival in advanced gastric carcinoma patients.
Yaman E; Coskun U; Sancak B; Buyukberber S; Ozturk B; Benekli M
Int Immunopharmacol; 2010 Jul; 10(7):719-22. PubMed ID: 20362077
[TBL] [Abstract][Full Text] [Related]
18. Serum vascular endothelial growth factor as a predictive factor in metronomic (weekly) Paclitaxel treatment for advanced head and neck cancer.
Caballero M; Grau JJ; Blanch JL; Domingo-Domenech J; Auge JM; Jimenez W; Bernal-Sprekelsen M
Arch Otolaryngol Head Neck Surg; 2007 Nov; 133(11):1143-8. PubMed ID: 18025320
[TBL] [Abstract][Full Text] [Related]
19. M30/M65 ratio predicts the outcome of paclitaxel chemotherapy for NSCLC.
Chu T; Jiang L; Ying W; Han B
Clin Transl Oncol; 2017 Mar; 19(3):326-331. PubMed ID: 27468866
[TBL] [Abstract][Full Text] [Related]
20. Inverse correlation between serum PGE2 and T classification in head and neck cancer.
Hambek M; Baghi M; Wagenblast J; Schmitt J; Baumann H; Knecht R
Head Neck; 2007 Mar; 29(3):244-8. PubMed ID: 17123309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
